Skip to main content
menu

Richard G. Moore, M.D.

Contact Information

Phone Numbers

Appointment: (585) 442-8020

Administrative: (585) 442-8020

Office: (585) 442-8020

Fax: (585) 442-8039

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Obstetrics & Gynecology

Biography

I believe all patients should be treated with compassion, along with an individualized plan for their treatment and care utilizing a multidisciplinary team approach. We approach each of our patients with the philosophy of "What would you want done for your loved one?" (Quote from Cornelius "Skip" Granai, III, M.D.)

Gynecologic oncology is a unique subspecialty that provides for the participation in all parts of a patient's care. The opportunity to be involved in such a personal experience during a patient's life -- from the time of diagnosis through surgery to managing chemotherapy and participating in all aspects of a woman's care -- is an honor and privilege.

My areas of expertise include robotic surgery for ovarian, endometrial and cervical malignancies, as well as sentinel lymph node mapping for endometrial, cervical and vulvar malignancies, and ovarian cancer biomarker research for the early detection and management of ovarian cancer.

Conditions I Treat:

- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Endometrial cancer
- Cervical cancer
- Vaginal cancer
- Vulvar cancer

Professional Background

Richard G. Moore, M.D., FACOG, FACS, joined UR Medicine's Obstetrics and Gynecology as the Director of the Gynecologic Oncology Division on October 1, 2015. Dr. Moore will also lead Wilmot Cancer Institute's Gynecology Service Line and serve as Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers.

Dr. Moore comes to UR Medicine from Brown University and Women & Infants Hospital of Rhode Island. A native of Montreal, Quebec, Canada, Dr. Moore graduated from the University of Alberta Medical School in Edmonton. He completed his residency at Eastern Virginia Graduate School of Medicine, where he also served as Administrative Chief Resident. He completed a fellowship in Gynecologic Oncology and Breast Surgery at Women & Infants Hospital/Brown University. Dr. Moore joined the faculty at Women and Infants/Brown University after leaving fellowship. He served as the Associate Director of the Program in Women's Oncology since 2009 and was the Director of the Center for Biomarkers and Emerging Technology as well as the Molecular Therapeutics laboratory.
Dr. Moore is board-certified in gynecologic oncology and is a fellow of the American College of Obstetricians and Gynecologists and a fellow of the American College of Surgeons.
In addition to his clinical interest in ovarian and endometrial cancers, Dr. Moore is recognized internationally as a leading expert on the use of biomarkers to detect ovarian cancer. He led the team that developed the Risk of Ovarian Malignancy Algorithm (ROMA), a test that is cleared for use in Europe and Asia and was recently cleared by the U.S. Food and Drug Administration to detect ovarian cancer in women who have an ovarian cyst or pelvic mass.
Dr. Moore will see patients at 125 Lattimore Road, Suite 258 and will perform surgeries at Highland Hospital, which has been awarded the Gold Seal of Approval by the Joint Commission and leads the state in the number of minimally invasive, robotic surgeries for gynecologic cancer performed each year.

Credentials

Specialties

    Education

    1993
    MD | University of Alberta School of Medicine (Canada)

    Post-doctoral Training & Residency

    07/01/1999 - 06/30/2002
    Fellowship in Gynecologic Oncology at Brown University School of Medicine

    07/01/1994 - 06/30/1997
    Residency in Internship/Residency at Eastern Virginia Medical School-GME

    07/01/1993 - 06/30/1994
    Internship in Obstetrics & Gynecology at Eastern Virginia Medical School-GME

    VIEW ALL expand_more

    Awards

    2015
    Consumer's Research Council of America
    Sponsor: Guide to America's Top Obstetricians and Gynecologists

    2014 - 2014
    New England Association of Gynecologic Oncologists
    Sponsor: Basic Science Paper Award. Mentee: Elizabeth Lokich, MD. HE4 ex
    Location: Newport RI,

    2014
    Rhode Island Monthly Journal, 2014
    Sponsor: Rhode Island Top Doc

    2013
    AACC's Outstanding Speaker Award for 2013
    Sponsor: American Association of clinical Chemists

    2013
    Consumer's Research Council of America
    Sponsor: Guide to America's Top Obstetricians and Gynecologists

    2013
    Rhode Island Monthly Journal, 2013
    Sponsor: Rhode Island Top Doc

    2012
    Rhode Island Monthly Journal, 2012
    Sponsor: Rhode Island Top Doc

    2012
    Consumer's Research Council of America
    Sponsor: Guide to America's Top Obstetricians and Gynecologists

    2011
    Providence Business News Innovation Awards 2011
    Sponsor: For the "Artificial Ovary
    Location: Brown University and Women and Infants Hospital

    2011
    Consumer's Research Council of America
    Sponsor: Guide to America's Top Obstetricians and Gynecologists

    2010
    Time Magazine: Top ten Medical Breakthroughs for 2010
    Sponsor: In vitro maturation of oocytes via the prefabricated self-assem

    2008
    New England Association of Gynecologic Oncologists
    Sponsor: Comparison of a novel multiple biomarker assay to the risk of ma
    Location: Cape Cod

    2008
    New England Association of Gynecologic Oncologists
    Sponsor: Differential expression of CA125 and a novel serum tumor marker
    Location: Cape Cod

    2008
    Full Time Faculty Excellence in Teaching Award

    2008
    Teaching Award from Chief Residents: Full Time Faculty

    2007 - 2007
    SGO Clinical Practice Science Poster Award
    Sponsor: sentinel lymph node dissection alone with conservative ...
    Location: San Diego, CA

    2006
    Medical Student Teaching Award
    Sponsor: BioMed 351
    Location: Brown University

    2006
    2006 Outstanding faculty mentorship award; from the resident graduating class of 2006

    2005
    New England Association of Gynecologic Oncology
    Sponsor: Long term follow-up of patients with stage I and II vulvar ...

    2002
    New England Association of Gynecologic Oncologists
    Sponsor: Sentinel node identification and the ability to detect ...

    1997
    The American Association of Gynecologic Laparoscopists Award

    1996 - 1997
    Resident of the Year

    1996 - 1997
    Administrative Chief Resident

    1996
    Gynecologic Oncology Resident Award

    1996
    Society of Assisted Reproductive Medicine Award

    VIEW ALL expand_more

    Clinical Trials

    A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

    Lead Researcher: Richard G Moore

    This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.

    View Study Details

    NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

    Lead Researcher: Richard G Moore

    This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.

    View Study Details

    A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

    Lead Researcher: Richard G Moore

    This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.

    View Study Details

    A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

    Lead Researcher: Richard G Moore

    This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

    View Study Details

    EMBER2 Study: Evaluation of multiple biomarkers to estimate risk of cancer in gynecology patients presenting with a pelvic mass (ANG-006)

    Lead Researcher: Richard G Moore

    The purpose of this study is to validate and refine a technology that can help physicians determine whether an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous) using a blood test. The specific technology is called ParsortixTM PC1 system, a semi-automated system capable of capturing and harvesting rare cells for subsequent analysis from blood based on the size and deformability of the cells.

    View Study Details

    Patents

    Patent Title: Therapy for Malignant Disease Comprising the Inhibition of Human Epididymal Secretory Protein E4 and Immune Checkpoint Inhibitors
    Patent #: 2,981,068
    Issue Date: Dec 14, 2021
    Country: Canada
    Invented By: Richard G Moore, Rakesh K Singh, Naohiro Yano

    Patent Title: Therapy for Malignant Disease
    Patent #: 10,376,535
    Issue Date: Aug 13, 2019
    Country: United States
    Invented By: Richard G Moore, Rakesh K Singh, Naohiro Yano

    Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
    Patent #: 3311165
    Issue Date: Dec 09, 2020
    Country: Europe
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
    Patent #: FR3311165
    Issue Date: Dec 09, 2020
    Country: France
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
    Patent #: DE3311165
    Issue Date: Dec 09, 2020
    Country: Germany
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
    Patent #: GB3311165
    Issue Date: Dec 09, 2020
    Country: United Kingdom
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
    Patent #: 11,034,719
    Issue Date: Jun 15, 2021
    Country: United States
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
    Patent #: 3128996
    Issue Date: Jun 02, 2021
    Country: Europe
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
    Patent #: FR3128996
    Issue Date: Jun 02, 2021
    Country: France
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
    Patent #: DE3128996
    Issue Date: Jun 02, 2021
    Country: Germany
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
    Patent #: GB3128996
    Issue Date: Jun 02, 2021
    Country: United Kingdom
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
    Patent #: 9,982,010
    Issue Date: May 29, 2018
    Country: United States
    Invented By: Richard G Moore, Rakesh K Singh

    Patent Title: 7-Dehydrocholesterol Derivatives and Methods Using Same
    Patent #: 10,683,324
    Issue Date: Jun 16, 2020
    Country: United States
    Invented By: Richard G Moore, Rakesh K Singh

    VIEW ALL expand_more

    Publications

    Journal Articles

    3/6/2024
    Campbell TM, Campbell EK, Culakova E, Blanchard LM, Wixom N, Guido JJ, Fetten J, Huston A, Shayne M, Janelsins MC, Mustian KM, Moore RG, Peppone LJ. "A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes." Breast cancer research and treatment.. 2024 Mar 6; Epub 2024 Mar 06.

    2/28/2024
    Kim K, Khazan N, Rowswell-Turner RB, Singh RK, Moore T, Strawderman MS, Miller JP, Snyder CWA, Awada A, Moore RG. "Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer." Cancers.. 2024 Feb 28; 16(5)Epub 2024 Feb 28.

    1/9/2024
    Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, Bast RC. "Normal Risk Ovarian Screening Study: 21-Year Update." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2024 Jan 9; :JCO2300141. Epub 2024 Jan 09.

    Books & Chapters

    2011
    Chapter Title: Breast Development and Anatomy
    Book Title: Clinical Obstetrics and Gynecology
    Author List: Sonali Pandya and Richard G. Moore
    Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011

    2011
    Chapter Title: Management of Ovarian Cysts and Adnexal Masses
    Book Title: Precis Gynecology
    Author List: Richard G. Moore and Shannon MacLaughlan
    Published By: Precis: Gynecology 2011

    2011
    Chapter Title: Forward
    Book Title: Clinical Obstetrics and Gynecology,
    Author List: James W. Orr and Richard G. Moore
    Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011

    VIEW ALL PUBLICATIONS

    Reviews

    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.